Vimarsana
Biggest News Aggregation in the World

Novel Methods News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Novel Methods. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Novel Methods Today - Breaking & Trending Today

Correlative Microscopy: Combining Techniques for Deeper Insight - Vimarsana News

Correlative Microscopy: Combining Techniques for Deeper Insight

In this article, we explore the benefits correlative microscopy can bring to nanoscience research. Continue reading to learn more.

Conformal Medical Selected as Powerhouse MedTech Company of the Year by New England Venture Capital Association's 2023 NEVY Awards - Vimarsana News

Conformal Medical Selected as Powerhouse MedTech Company of the Year by New England Venture Capital Association's 2023 NEVY Awards

NASHUA, N.H., Dec. 12, 2023 /PRNewswire/ -- Conformal Medical, Inc. announced today that the company was selected as the Powerhouse MedTech Compan...

Conformal Medical Announces Compelling One-Year Data from its Left Atrial Appendage Occlusion (LAAO) Early Feasibility Study - Vimarsana News

Conformal Medical Announces Compelling One-Year Data from its Left Atrial Appendage Occlusion (LAAO) Early Feasibility Study

/PRNewswire/ -- Conformal Medical, Inc. announced today the positive one-year results from the company's CONFORMAL Early Feasibility Study (EFS). Dr. William...

NewsNow: DARPA news | Breaking News & Search 24/7 - Vimarsana News

NewsNow: DARPA news | Breaking News & Search 24/7

Read the latest DARPA headlines, on NewsNow: the one-stop shop for DARPA news

Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care - Vimarsana News

Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care

AstraZeneca to proceed with regulatory filings to convert from conditional to full approval in the US and EU ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa in... | June 5, 2023